Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice

Microbes and Infection

Volumn 16, Issue 6, 2014, Pages 512-517

  Takemura Uchiyama, Iyo ^a,b   Uchiyama, Jumpei ^a,c   Osanai, Makoto ^a   Morimoto, Norihito ^b   Asagiri, Tadashi ^b   Ujihara, Takako ^c   Daibata, Masanori ^a,c   Sugiura, Tetsuro ^b   Matsuzaki, Shigenobu ^a,c  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b KOCHI MEDICAL SCHOOL HOSPITAL   (Japan)

^c KOCHI UNIVERSITY   (Japan)

Author keywords

Bacteriophage; Mouse; Podoviridae; Therapeutic; Therapy

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; IN VITRO STUDY; LETHALITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SEPTICEMIA; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; ANIMAL; BIOLOGICAL THERAPY; CROSS INFECTION; DISEASE MODEL; LUNG; MICROBIOLOGY; PATHOLOGY; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS PHAGE; VIROLOGY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS; PODOVIRIDAE; STAPHYLOCOCCUS AUREUS;

ANIMALS; BIOLOGICAL THERAPY; CROSS INFECTION; DISEASE MODELS, ANIMAL; LUNG; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS PHAGES;

EID: 84902772230     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.02.011     Document Type: Article

References (23)

1. Moellering R.C. MRSA: the first half century. J Antimicrob Chemother 2012, 67:4-11.
2. Kollef M.H., Micek S.T. Staphylococcus aureus pneumonia: a "superbug" infection in community and hospital settings. Chest 2005, 128:1093-1097.
3. DeRyke C.A., Lodise T.P., Rybak M.J., McKinnon P.S. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 2005, 128:1414-1422.
4. Rubinstein E., Kollef M.H., Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008, 46:S378-S385.
5. O'Flaherty S., Ross R.P., Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 2009, 33:801-819.
6. Lu T.K., Koeris M.S. The next generation of bacteriophage therapy. Curr Opin Microbiol 2011, 14:524-531.
7. Carmody L.A., Gill J.J., Summer E.J., Sajjan U.S., Gonzalez C.F., Young R.F., et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 2010, 201:264-271.
8. Chhibber S., Kaur S., Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 2008, 57:1508-1513.
9. Debarbieux L., Leduc D., Maura D., Morello E., Criscuolo A., Grossi O., et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010, 201:1096-1104.
10. Takemura-Uchiyama I., Uchiyama J., Kato S.I., Inoue T., Ujihara T., Ohara N., et al. Evaluating efficacy of bacteriophage therapy against Staphylococcus aureus infections using a silkworm larval infection model. FEMS Microbiol Lett 2013, 347:52-60.
11. Enright M.C., Day N.P., Davies C.E., Peacock S.J., Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000, 38:1008-1015.
12. Edwards L.A., O'Neill C., Furman M.A., Hicks S., Torrente F., Pérez-Machado M., et al. Enterotoxin-producing staphylococci cause intestinal inflammation by a combination of direct epithelial cytopathy and superantigen-mediated T-cell activation. Inflamm Bowel Dis 2012, 18:624-640.
13. Shields P., Tsang A.Y. Mannitol salt agar plates protocols 2006, Protocols, American Society for Microbiology, Washington, DC, [accessed 10.09.12]. http://www.microbelibrary.org.
14. Matsuzaki S., Yasuda M., Nishikawa H., Kuroda M., Ujihara T., Shuin T., et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11. J Infect Dis 2003, 187:613-624.
15. Bozza F.A., Salluh J.I., Japiassu A.M., Soares M., Assis E.F., Gomes R.N., et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007, 11:R49.
16. Brüssow H. Phage therapy: the Escherichia coli experience. Microbiology 2005, 151:2133-2140.
17. Takano T., Hung W.C., Shibuya M., Higuchi W., Iwao Y., Nishiyama A., et al. A new local variant (ST764) of the globally disseminated ST5 lineage of hospital-associated methicillin-resistant Staphylococcus aureus (MRSA) carrying the virulence determinants of community-associated MRSA. Antimicrob Agents Chemother 2013, 57:1589-1595.
18. Uchiyama J., Takemura I., Satoh M., Kato S., Ujihara T., Akechi K., et al. Improved adsorption of an Enterococcus faecalis bacteriophage φEF24C with a spontaneous point mutation. PLoS One 2011, 6:e26648.
19. Rhoads D.D., Wolcott R.D., Kuskowski M.A., Wolcott B.M., Ward L.S., Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009, 18:237-243.
20. Wright A., Hawkins C.H., Anggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009, 34:349-357.
21. Górski A., Miedzybrodzki R., Borysowski J., Dabrowska K., Wierzbicki P., Ohams M., et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 2012, 83:41-71.
22. Vybiral D., Takác M., Loessner M., Witte A., von Ahsen U., Bläsi U. Complete nucleotide sequence and molecular characterization of two lytic Staphylococcus aureus phages: 44AHJD and P68. FEMS Microbiol Lett 2003, 219:275-283.
23. Vandersteegen K., Mattheus W., Ceyssens P.J., Bilocq F., De Vos D., Pirnay J.P., et al. Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 2011, 6:e24418.